{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:01:53Z","timestamp":1792803713658,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.contraception.2024.110727","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T01:43:17Z","timestamp":1729129397000},"page":"110727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Lower reporting of venous thromboembolisms events with natural estrogen-based combined oral contraceptives compared to ethinylestradiol-containing pills: A disproportionality analysis of the Eudravigilance database"],"prefix":"10.1016","volume":"142","author":[{"given":"Marie","family":"Didembourg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9d\u00e9a","family":"Locquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babel Tsague","family":"Tchimchoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Dogn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Beaudart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-5298","authenticated-orcid":false,"given":"Jonathan","family":"Douxfils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2024.110727_bib1","unstructured":"Food and Drug Administration. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints - CHC-CVD final report 111022v2. 2011. \u3008https:\/\/www.fda.gov\/media\/82335\/download\u3009. (Accessed on 26 Dec 2019)."},{"key":"10.1016\/j.contraception.2024.110727_bib2","first-page":"CD010813","article-title":"Combined oral contraceptives: venous thrombosis","volume":"2014","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2024.110727_bib3","unstructured":"European Medicines Agency. Assessment report for combined hormonal contraceptives containing medicinal products \u2014 Procedure number: EMEA\/H\/A-31\/1356. 2014. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/referral\/combined-hormonal-contraceptives-article-31-referral-prac-assessment-report_en.pdf\u3009. (Accessed on 13 Jan 2020)."},{"key":"10.1016\/j.contraception.2024.110727_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ijgo.12455","article-title":"A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception","volume":"141","author":"Dragoman","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.contraception.2024.110727_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.769187","article-title":"Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk","volume":"12","author":"Morimont","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.contraception.2024.110727_bib6","unstructured":"The Faculty of Sexual and Reproductive Healthcare. FSRH guideline - Combined hormonal contraception (amended October 2023). 2019. \u3008https:\/\/www.fsrh.org\/Public\/Documents\/fsrh-guideline-combined-hormonal-contraception.aspx\u3009. (Accessed on 23 August 2024)."},{"key":"10.1016\/j.contraception.2024.110727_bib7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/13625187.2011.604450","article-title":"Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism","volume":"16","author":"Agren","year":"2011","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2024.110727_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/11591200-000000000-00000","article-title":"Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate\/dienogest versus ethinylestradiol\/levonorgestrel","volume":"11","author":"Klipping","year":"2011","journal-title":"Drugs R D"},{"key":"10.1016\/j.contraception.2024.110727_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/BF03261968","article-title":"A pathway to improved prospective observational post-authorization safety studies","volume":"35","author":"Kiri","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.contraception.2024.110727_bib10","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) \u2014 Module VIII \u2013 Postauthorisation safety studies (Rev 3) \u2014 EMA\/813938\/2011 Rev 3*. 2017. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf\u3009. (Accessed on 3 Oct 2024)."},{"key":"10.1016\/j.contraception.2024.110727_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/13625187.2021.1987410","article-title":"Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17beta-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism","volume":"26","author":"Reed","year":"2021","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2024.110727_bib12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/AOG.0000000000005509","article-title":"Venous thromboembolic risk of estradiol valerate-dienogest compared with ethinyl estradiol-levonorgestrel combined oral contraceptives","volume":"143","author":"Bauerfeind","year":"2024","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2024.110727_bib13","doi-asserted-by":"crossref","first-page":"1428597","DOI":"10.3389\/fendo.2024.1428597","article-title":"Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis","volume":"15","author":"Douxfils","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.contraception.2024.110727_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100155","article-title":"Hormonal therapies and venous thrombosis: considerations for prevention and management-a reappraisal","volume":"7","author":"Douxfils","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.contraception.2024.110727_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/17512433.2022.2054413","article-title":"Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause","volume":"15","author":"Gerard","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.contraception.2024.110727_bib16","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","article-title":"Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters","volume":"102","author":"Douxfils","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110727_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.contraception.2021.01.001","article-title":"Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone","volume":"103","author":"Klipping","year":"2021","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110727_bib18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.contraception.2021.05.002","article-title":"Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results","volume":"104","author":"Creinin","year":"2021","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110727_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/1471-0528.16840","article-title":"Estetrol-drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia","volume":"129","author":"Gemzell-Danielsson","year":"2022","journal-title":"BJOG"},{"key":"10.1016\/j.contraception.2024.110727_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.contraception.2022.10.004","article-title":"Tolerability and safety of the estetrol\/drospirenone combined oral contraceptive: pooled analysis of two multicenter, open-label phase 3 trials","volume":"116","author":"Chen","year":"2022","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110727_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.contraception.2024.110727_bib22","unstructured":"European Medicines Agency. EudraVigilance system overview. 2024. \u3008https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance\/eudravigilance-system-overview\u3009. (Accessed on 1 May 2024)."},{"key":"10.1016\/j.contraception.2024.110727_bib23","unstructured":"European Medicines Agency. Guideline on the use of statistical signal detection methods in the Eudravigilance Data Analysis System. 2007. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/draft-guideline-use-statistical-signal-detection-methods-eudravigilance-data-analysis-system_en.pdf\u3009. (Accessed on 1 May 2024)."},{"key":"10.1016\/j.contraception.2024.110727_bib24","first-page":"1635","article-title":"Practical statistics for medical research","volume":"10","author":"Altman","year":"1991","journal-title":"Stat\u00a0Med"},{"key":"10.1016\/j.contraception.2024.110727_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.thromres.2022.09.007","article-title":"Estetrol is not a SERM but a NEST and has a specific safety profile on coagulation","volume":"232","author":"Douxfils","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.contraception.2024.110727_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/clinem\/dgac511","article-title":"Low thrombin generation in users of a contraceptive containing estetrol and drospirenone","volume":"108","author":"Morimont","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2024.110727_bib27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.thromres.2020.08.006","article-title":"Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et al. entitled \"Estrogen and thrombosis: A bench to bedside review\" (Thrombosis Research 192 (2020) 40-51)","volume":"193","author":"Morimont","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.contraception.2024.110727_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.thromres.2010.01.045","article-title":"Mechanisms of estrogen-induced venous thromboembolism","volume":"126","author":"Tchaikovski","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.contraception.2024.110727_bib29","first-page":"117","volume":"22","author":"Douxfils","year":"2023","journal-title":"Prz Menopauzalny"},{"key":"10.1016\/j.contraception.2024.110727_bib30","first-page":"293","article-title":"Prediction of venous thromboembolism risk associated with combined oral contraceptives: an exploratory model","author":"Morimont","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.contraception.2024.110727_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2024.110375","article-title":"Systematic analysis of combined oral contraceptive prescription patterns in psychotropic drug users across twelve European countries","volume":"132","author":"Boehnke","year":"2024","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782424004360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782424004360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:33:24Z","timestamp":1740357204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782424004360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":31,"alternative-id":["S0010782424004360"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2024.110727","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower reporting of venous thromboembolisms events with natural estrogen-based combined oral contraceptives compared to ethinylestradiol-containing pills: A disproportionality analysis of the Eudravigilance database","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2024.110727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110727"}}